Stanford Medicine
Gastric Cancer Summit 2020
March 5th & 6th, 2020
555 Salvatierra Walk, Stanford, CA 94305
# March 5th - Sessions

- **Session 1**: Overview of Gastric Cancer in the US
- **Session 2**: Current Strategies for Gastric Cancer Screening in Asia
- **Session 3**: Health Policy for Gastric Cancer
- **Session 4**: Advocacy

# March 6th - Sessions

- **Session 1**: International Perspectives on Gastric Cancer Prevention
- **Session 2**: Microbes and Gastric Cancer
- **Session 3**: Gastric Cancer 2050, Shifting Burdens and Demographics
- **Session 4**: Advancing Early Detection

# Contents

- Thursday March 5th Speakers and Bios
- Friday March 6th Speakers and Bios
- Center for Asian Health Research and Education Mission
- Beyond the Gastric Cancer Summit
Welcome letter from the Directors of the Gastric Cancer Summit

The Stanford Center for Asian Health Research and Education (CARE) and the Stanford Division of Gastroenterology and Hepatology welcomes you to the inaugural Gastric Cancer Summit at Stanford. This multi-disciplinary Summit brings together physicians, researchers, policy makers, patients, and advocacy groups from around the United States and the world, to share experiences and discoveries, with the common goal of creating a roadmap to address the prevention, early detection, and treatment of gastric cancer.

In the United States, this burden of gastric cancer falls disproportionately on ethnic minorities and immigrant communities, especially Asians. There exists no coherent national strategy for the early detection of gastric cancer, even among identified high-risk groups. The under-recognition of gastric cancer risk among minority communities may be one of the most significant unaddressed healthcare disparities in the United States.

This Summit will bring together a community of those dedicated to improving the prevention, early detection, and treatment of gastric cancer, and foster future collaboration in this effort.

JOO HA HWANG, MD, PhD
Professor of Medicine
Associate Director, CARE at Stanford University
Division of Gastroenterology and Hepatology
Stanford University School of Medicine

ROBERT HUANG, MD, MS
Instructor of Medicine
Associated Faculty, CARE at Stanford University
Division of Gastroenterology and Hepatology
Stanford University School of Medicine

BRYANT LIN, MD, MS
Clinical Associate Professor, Medicine
Co-Director, CARE at Stanford University
Division of Primary Care & Population Health
Stanford University School of Medicine

LATHA PALANIAPPAN, MD, MS
Professor of Medicine
Co-Director, CARE at Stanford University
Division of Primary Care & Population Health
Stanford University School of Medicine
March 5th - Sessions

7:30 - 8:30
Welcome Breakfast

8:30 - 8:45
Introductions
Joo Ha Hwang, MD, PhD | Robert Huang, MD, MS | Latha Palaniappan, MD, MS | Bryant Lin, MD, MSE

Session 1: Overview of Gastric Cancer in the US
Moderator: John Inadomi, MD

8:45 - 9:00
Overview of the current status of gastric cancer in the US
Joo Ha Hwang, MD, PhD | Stanford University

9:00 - 9:15
The role of surgery in the treatment of early gastric cancer in the US
Yanghee Woo, MD | City of Hope

9:15 - 9:30
Ethnic and racial differences in gastric cancer incidence in the US
Dennis Deapen, DPH and EunJung Lee, PhD | University of Southern California

9:30 - 9:45
Cost-effectiveness of gastric cancer screening in the US
Shailja Shah, MD, MPH | Vanderbilt University

9:45 - 10:10
Panel Discussion
Joo Ha Hwang | Yanghee Woo | Dennis Deapen | EunJung Lee | Shailja Shah

10:10 - 10:30
Break

Session 2: Current Strategies for Gastric Cancer Screening in Asia
Moderator: Robert Huang, MD, MS

10:30 - 10:50
Strategies for gastric cancer screening and treatment of early neoplasia
Hwoon-Yong Jung, MD, PhD | Ulsan University

10:50 - 11:10
Gastric cancer screening program in Japan
Chisato Hamashima, MD, DrMedSc | Teikyo University

11:10 - 11:30
Gastric cancer screening program in Korea
Il Ju Choi, MD | National Cancer Center, Korea

11:30 - 11:50
Panel Discussion
Hwoon-Yong Jung | Chisato Hamashima | Il Ju Choi

11:50 - 13:00
Lunch

13:00 - 13:10
Welcome Remarks
Dean Lloyd Minor, MD
March 5th - Sessions

Session 3: Health Policy for Gastric Cancer
Moderator: Joo Ha Hwang, MD, PhD

13:10 - 13:40
Keynote address: Approach to addressing healthcare disparities for Asians in the US
Howard Koh, MD, MPH | Harvard University

13:40 - 13:55
Is there a sufficient disease burden in the US to warrant gastric cancer screening in high-risk populations?
Chin Hur, MD, MPH | Columbia University

13:55 - 14:10
Should we be screening for H. pylori and treating in high-risk groups?
Meira Epplein, PhD | Duke University

14:10 - 14:25
NIH Efforts at Gastric Cancer Prevention
Asad Umar, DVM, PhD | National Institutes of Health

14:25 - 14:45
Panel Discussion
Howard Koh | Chin Hur | Meira Epplein | Julie Parsonnet | Asad Umar

14:45 - 15:05
Break

Session 4: Advocacy
Moderator: Howard Koh, MD, MPH

15:05 - 15:20
What can be done by patient advocates to impact health policy – the Hepatitis B story
Samuel So, MD | Stanford University

15:20 - 15:35
What can patient advocacy groups do to impact health policy
Aki Smith | Hope for Stomach Cancer

15:35 - 15:50
The role of societies in addressing health disparities: Are we ready to establish guidelines for gastric cancer screening in the US
John Inadomi, MD | University of Washington

15:50 - 16:05
Next steps: The path forward
Robert Huang, MD, MS | Stanford University

16:05 - 16:25
Panel Discussion
Samuel So | Aki Smith | John Inadomi | Robert Huang | David Greenwald

16:25 - 16:30
Close
Joo Ha Hwang & Robert Huang

16:30 - 17:30
Wine and Cheese Reception
Overview of Gastric Cancer in the US

Joo Ha Hwang, MD, PhD
Stanford University
“Overview of the current status of gastric cancer in the US”

Dr. Joo Ha Hwang has both a clinical and research interest in improving the early detection of gastric cancer. He is the Principal Investigator of the Gastric Precancerous conditions Study (GAPS), a prospective study of patients with gastric intestinal metaplasia and other precancerous conditions. He actively participates in public policy efforts to increase recognition of gastric cancer risk among high-risk populations. Clinically, he serves as the Director of Interventional Endoscopy at Stanford and performs endoscopic submucosal dissection (ESD) for the resection of pre-malignant and early malignant lesions in the gastrointestinal tract, with a particular interest in gastric cancer. Dr. Hwang received his M.D. from the University of Chicago and his Ph.D. in Bioengineering from the University of Washington.

Yanghee Woo, MD
City of Hope
“Potential application of liquid biopsy techniques for earlier detection of gastric cancer”

Dr. Yanghee Woo is a surgeon investigator internationally recognized for her expertise in gastric cancer and robotic surgery. Her clinical practice focuses on treating gastric cancer patients with the highest volume in California. Dr. Woo’s research is focused on immune biomarker discovery of prognosis and treatment response actively conducting preclinical studies to develop immune mediated targeted viral oncolytic therapy against unresectable gastric and pancreatic cancers with grant funding in this area.
Eunjung Lee, PhD
University of Southern California
“Ethnic and racial differences in gastric cancer incidence in the US”

Dr. Eunjung Lee is an Associate Professor of Research Preventive Medicine, her recent research interests are focused on understanding the impact of environmental chemicals on breast cancer risk in diverse populations and identifying cancer disparity in less well-studied Asian subgroups, including Korean and Vietnamese Americans in California.

Shailja Shah, MD, MPH
Vanderbilt University
“Cost-effectiveness of gastric cancer screening in the United States”

Dr. Shailja Shah is an Assistant Professor of Medicine and practicing gastroenterologist at Vanderbilt University Medical Center and the Nashville VA Medical Center. She completed her internal medicine residency at the University of California, San Francisco, and gastroenterology fellowship at the Mount Sinai Hospital in New York City. Dr. Shah is a funded clinician investigator whose research interests are focused on Helicobacter pylori epidemiology and associated diseases, inflammation-associated GI carcinogenesis, as well as implementation of gastric cancer prevention and early detection efforts.

Dennis Deapen, DPH
University of Southern California
“Ethnic and racial differences in gastric cancer incidence in the US”

Dr. Dennis Deapen is Professor of Preventive Medicine at the USC School of Medicine. He has been Director of the Los Angeles SEER cancer registry since 1988. He has created or led large, long-term cohort studies of cancer risk and has been author or co-author of over 180 peer-reviewed publications.
Current Strategies for Gastric Cancer Screening in Asia

Hwoon Yong Jung, MD, PhD
Ulsan University
“Strategies for gastric cancer screening and treatment of early neoplasia”

Dr. Hwoon Yong Jung is a Professor of Medicine at Ulsan University. He is a therapeutic endoscopist at Asan Medical Center, the largest hospital in Seoul, Korea. Major interests are therapeutic endoscopy for GI cancer, Helicobacter, and esophageal motility. “Gastric cancer is closely related with Helicobacter infection. Screening endoscopy can help detecting gastric cancer at early stage and provide the chance to receive Endoscopic resection.”

Chisato Hamashima, MD, DrMedSc
Teikyo University
“Gastric cancer screening program in Japan”

Dr. Chisato Hamashima is a Professor on Health Policy Section, Division of Nursing Faculty of Medical Technology, Teikyo University (Tokyo, Japan).

Dr. Hamashima was intricately involved in the development of cancer screening guidelines for national programs at the National Cancer Center for 15 years and continues collaboration on these programs.
IL JU Choi, MD  
NATIONAL CANcer CENTER, KOREA  
“Gastric cancer screening program in Korea”

Dr. Il Ju Choi is a staff physician at the Center for Gastric Cancer, and an adjunct Professor at the Departments of Cancer Control and Population Health in the National Cancer Center Korea. His major research interests are gastric cancer prevention studies with H. pylori treatment and with endoscopic screening as well as endoscopic treatment of early gastric cancer.

Lunch Break

Lloyd B. Minor, MD  
Stanford University

Dr. Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012.

As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children’s Health and Lucile Packard Children’s Hospital Stanford. He also oversees the quality of Stanford Medicine’s physician practices and growing clinical networks.

With Dr. Minor’s leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in Precision Health. The next generation of health care, Precision Health is focused on keeping people healthy and providing care that is tailored to individual variations. It’s predictive, proactive, preemptive, personalized, and patient-centered.
March 5th - Session Three Speakers

Moderator: Joo Ha Hwang, MD, PhD

Health Policy for Gastric Cancer

Howard Koh, MD, MPH
Harvard University
“Keynote address: Approach to addressing healthcare disparities for Asians in the US”

Dr. Howard K. Koh is the Harvey V. Fineberg Professor of the Practice of Public Health Leadership at the Harvard T.H. Chan School of Public Health and the Harvard Kennedy School as well as Faculty Co-Chair of the Harvard Advanced Leadership Initiative. In these roles since 2014, he advances leadership education and training at the Harvard T.H. Chan School of Public Health as well as across Harvard University. Dr. Koh served as the 15th United States Assistant Secretary for Health in the Obama Administration.

Meira Epplein, PhD
Duke University
“Is there a sufficient disease burden in the US to warrant gastric cancer screening in high-risk populations?”

Dr. Meira Epplein is a cancer epidemiologist interested in modifiable risk factors in under-served populations, with a focus on the association of infection and cancer. Dr. Epplein’s research program has centered around the bacteria Helicobacter pylori, a spiral, gram-negative bacterium that infects approximately 50% of the world’s population, and is the leading carcinogenic infectious agent according to the International Agency for Research on Cancer. Her research seeks to understand the heterogeneity of H. pylori, to determine the most toxigenic forms of the bacteria so as to identify the highest risk populations which can then be targeted for antibiotic therapy, which has been shown to be effective for risk reduction. At the same time, she is committed to furthering our understanding of the co-factors involved in both H. pylori-associated disease risk and benefit.
Chin Hur, MD, MPH  
Columbia University  
“Is there a sufficient disease burden in the US to warrant gastric cancer screening in high-risk populations?”

Dr. Chin Hur is a Professor of Medicine and Epidemiology at Columbia University in New York. His research focus is on screening, surveillance and prevention of upper GI cancers including the stomach and esophagus. He directs a Healthcare Innovations Research and Evaluation center at Columbia University which focuses on applying cutting edge research techniques to optimize prediction and health outcomes.

Asad Umar, DVM, PhD  
National Institutes of Health  
“NIH Efforts at Gastric Cancer Prevention”

Dr. Asad Umar received his PhD in Biochemistry and Immunology at the Johns Hopkins University in Baltimore, MD, in 1993. He conducted his postdoctoral training in the laboratories of Patricia Gearhart in Baltimore, MD and Thomas Kunkel at the National Institutes of Environmental Health Sciences in Research Triangle Park, NC. Dr. Umar’s main scientific interest is to understand the molecular pathways during gastrointestinal carcinogenesis and applying molecularly targeted and immunologic interventions to prevent cancer. His research contributions are in deciphering the biochemical defects in Lynch syndrome and later published Revised Bethesda guidelines for LS. He oversees a wide variety of grants and contracts focusing on cancer prevention translational research, cancer screening, and clinical trials. Some of the major research areas and grants funded under his leadership include: Novel Mechanisms of NSAIDS/anti-inflammatory Agents in Cancer Prevention; Cancer Stem Cells’ Role in Cancer Prevention; Green Tea Polyphenon E for HCC Prevention; Role of DFMO in Cancer Prevention; National Polyp Screening Trial; Vitamin E and Selenium Skin Cancer Prevention Trial; the Calcium and Vitamin D Trial; and ACF as Surrogate Markers for Cancer Prevention.
March 5th - Session Four Speakers
Moderator: Howard Koh, MD, MPH

Advocacy

Samuel So, MD
Stanford University
“What can be done by patient advocates to impact health policy – the Hepatitis B story”

Dr. Samuel So is recognized worldwide for his expertise in chronic hepatitis B and primary liver cancer prevention, research, treatment and health policy. He served as a consultant for the FDA and was a member and co-chair of the U.S. Department of Health and Human Services Office of Minority Health’s Hepatitis B Expert Panel. He was also a member of the Board of Population Health and Public Health Practices of the Institute of Medicine of the National Academies, and a committee member of the 2010 IOM report on “Hepatitis and Liver Cancer: a national strategy for the prevention and control of hepatitis B and C”, and the 2016 National Academy of Sciences, Engineering and Medicine report on “Eliminating the Public Health Problem of Hepatitis B and C in the United States. He also serves as a special adviser on viral hepatitis for the World Health Organization Western Pacific regional office. In 2010, he received the CDC and ATSDR Honor Award for mobilizing people and resources in ways that have changed global public health policies related to hepatitis B, and was recognized in 2014 by the White House for global and national leadership in the prevention and control of viral hepatitis.

John Matthew Inadomi, MD
University of Washington
“The role of societies in addressing health disparities: Are we ready to establish guidelines for gastric cancer screening in the US”

Dr. John Inadomi is currently the Head of the Division of Gastroenterology at the University of Washington. Dr. Inadomi is the principal investigator or co-investigator on several NIH grants to conduct health services and outcomes research to optimize the management of gastrointestinal cancers, and develop novel interventions to increase screening to reduce mortality from cancer. He is currently an associate editor for the AGA journal Gastroenterology and has completed term memberships for the NIH HSOD and DDK-C study sections.
**Robert Huang, MD, MS**  
**Stanford University**  
“Next steps: The path forward”

Dr. Robert Huang is a gastroenterologist, epidemiologist, and Instructor at Stanford University. Dr. Huang’s research interests include the epidemiology of gastric cancer, racial and ethnic disparities in gastric cancer incidence and survival in the United States, and molecular risk-stratification of gastric precancerous conditions such as intestinal metaplasia. He is co-principal investigator of the Gastric Precancerous Conditions Study (GAPS) a cohort and bio-specimen repository of patients with gastric precancerous lesions based at Stanford.

---

**Aki Smith**  
**Hope for Stomach Cancer**  
“What can patient advocacy groups do to impact health policy?”

Dr. Aki Smith is a caregiver and patient advocate for her father, who was diagnosed with advanced stomach cancer. She’s Founder and Executive Director of Hope for Stomach Cancer, a nonprofit organization that provides resources to patients, caregivers, and loved ones facing stomach cancer while promoting early detection and prevention to the general and medical communities. Her vision is to bridge the gap between research and care.

---

**David Greenwald, MD**  
**Mount Sinai Hospital**

Dr. David Greenwald is currently the Director of Clinical Gastroenterology and Endoscopy at Mount Sinai Hospital in New York City and Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is currently President-Elect and a member of the Board of Trustees for the American College of Gastroenterology, and previously was the Chairman of the Board of Governors. He is a Board Member of GIQuI-C, the GI Quality Improvement Consortium and has been a member of the Steering Committee of the National Colorectal Cancer Roundtable, and is now the Co-Chair of that organization’s Public Relations and Social Media Committee. In New York, he is the co-chairman of the Citywide Colorectal Cancer Control Coalition (C5, having previously been co-Chairman of the Quality Subcommittee.
### March 6th - Sessions

**7:30 - 8:25**  
*Welcome Breakfast*

**8:25 - 8:30**  
**Introductions**  
Joo Ha Hwang, MD, PhD | Robert Huang, MD, MS

---

### Session 1: International Perspectives on Gastric Cancer Prevention  
**Moderator: Joo Ha Hwang, MD, PhD**

**8:30 - 8:50**  
*The Stand Up To Cancer Gastric Cancer Interception Team*  
Andrew Chan, MD, MPH | Harvard University

**8:50 - 9:10**  
*Novel molecular risk stratification tools in intestinal metaplasia: the Singaporean Experience*  
Khay Guan Yeoh, MD | National University of Singapore

**9:10 - 9:30**  
*Gastric Cancer campaigns in the South of Chile - Social accountability and scientific initiatives*  
Alejandro Corvalan, MD | Pontificia Universidad Catolica de Chile

**9:30 - 9:50**  
*Early detection approaches for the family of GI cancers*  
Matthew Young, PhD | National Institutes of Health

**9:50 - 10:05**  
**Panel Discussion**  
Andrew Chan | Khay Guan Yeoh | Alejandro Corvalan | Matthew Young | Constanza Camargo

**10:05 - 10:25**  
*Break*

---

### Session 2: Microbes and Cancer  
**Moderator: Meira Epplein, PhD**

**10:25 - 10:45**  
*Pathobiology of H. pylori-Induced Gastric Cancer*  
Richard Peek, MD | Vanderbilt University

**10:45 - 11:05**  
*Helicobacter pylori, Polyamines, and Gastric Cancer*  
Keith Wilson, MD | Vanderbilt University

**11:05 - 11:25**  
*EBV Associated Gastric Cancers*  
Charles Rabkin, MD | National Institutes of Health

**11:25 - 11:45**  
*Gastric Cancer from H. pylori’s perspective*  
Manuel Amieva, MD, PhD | Stanford University

**11:45 - 12:00**  
**Panel Discussion**  
Richard Peek | Keith Wilson | Charles Rabkin | Manuel Amieva

**12:00 - 13:00**  
*Lunch*
March 6th - Sessions

Session 3: Gastric Cancer 2050, Shifting Burdens and Demographics
Moderator: Julie Parsonnet, MD

13:00 - 13:20
Modeling Gastric Cancer into the 21st century
Fernando Alarid-Escudero, PhD | University of Minnesota

13:20 - 13:40
The Changing Face of Non-Cardia Gastric Adenocarcinoma
Constanza Camargo, PhD | National Institutes of Health

13:40 - 14:00
Gastric Cardia Cancer in Eastern and Western Populations
Christian C. Abnet, Ph.D, M.P.H. | National Institutes of Health

14:00 - 14:20
Gastric Cancer among Alaskan Natives
Michael Bruce, MD | Center for Disease Control

14:20 - 14:40
Panel Discussion
Fernando Alarid-Escudero | Constanza Camargo | Christian Abnet | Michael Bruce

14:40 - 15:00
Break

Session 4: Advancing Early Detection
Moderator: Robert Huang, MD

15:00 - 15:20
CDH1 testing in the age of multi-panel gene testing
Elena Martinez Stoffel, MD | University of Michigan

15:20 - 15:40
Advanced imaging for the detection of early-stage gastric cancer in hereditary diffuse gastric cancer (HDGC) syndrome
Jeremy Davis, MD | National Institutes of Health

15:40 - 16:00
Molecular pathways of gastric cancer and intestinal metaplasia, insights from single cell transcriptomics
Hanlee Ji, MD | Stanford University

16:00 - 16:20
Understanding the spectrum of gastric atrophy: OLGA and OLGIM staging systems
Blanca Piazuelo, MD | Vanderbilt University

16:20 - 16:40
Panel Discussion
Elena Martinez Stoffel | Jeremy Davis | Hanlee Ji | Blanca Piazuelo

16:40 - 17:00
Close
Joo Ha Hwang, MD, PhD | Robert Huang, MD, MS
International Perspectives on Gastric Cancer Prevention

Khay-Guan Yeoh, MD
National University of Singapore
“Novel molecular risk stratification tools in intestinal metaplasia: the Singaporean Experience.”

Dr. Khay-Guan Yeoh is Chief Executive, National University Health System and Professor of Medicine and Oncology at the National University of Singapore; he practices as a Senior Consultant at the Division of Gastroenterology and Hepatology, National University Hospital (NUH).

Matthew Young, PhD
National Institutes of Health
“Early Detection Approaches for the Family of GI Cancers”

Dr. Matthew Young is a Program Director the Cancer Biomarkers Research Group (CBRG), Division of Cancer Prevention, the National Cancer Institute. He is a Program Officer for the Early Detection Research Network (EDRN) Gastrointestinal (GI) Cancers collaborative group. His portfolio includes grant awards for colorectal, gastric and esophageal cancer. Dr. Young manages an Interagency Agreement with the National Institute of Standards and Technology (NIST), which in focused on developing reference material for liquid biopsy assays.
Alejandro Corvalan, MD
Pontificia Universidad Catolica de Chile
“Gastric Cancer campaigns in the South of Chile - Social accountability and scientific initiatives”

Dr. Alejandro Corvalan is Professor associate in the Faculty of Medicine of the Pontifical University Catholic of Chile, Santiago, Chile and investigator Principal of the Advanced Center of chronic disease (ACCDiS). The laboratory of Dr. Corvalan is aimed at basic levels cancer translational research, clinical and population. Your inquiries are mainly focused on epigenetics of cancer, with emphasis on the discovery and validation of coding and non-coding genes inactivated by methylation and/or microRNAs. These genes act not only in the pathogenesis of the cancer, but also as potential biomarkers for early diagnosis, monitoring of response to the treatment and development of new therapies. Through this research, his laboratory has discovered new potential biomarkers for early detection of gastric cancer, free plasma DNA-based (NCT01774266). It also participates in investigations related to the role of Epstein-Barr Virus (EBV) in gastric cancer and hereditary gastric cancer syndrome (HDGC).

Andrew Chan, MD, MPH
Harvard Medical School
“The Stand Up To Cancer Gastric Cancer Interception Team”

Dr. Andrew Chan is a Professor of Medicine at Harvard Medical School who specializes in familial gastrointestinal cancer syndromes and cancer prevention. As a molecular epidemiologist, his research focuses on the epidemiology of gastrointestinal cancer, chemoprevention, the gut microbiome, and novel strategies for interception and early detection.
Microbes and Gastric Cancer

Richard Peek, MD
Vanderbilt University
“Pathobiology of H. pylori-Induced Gastric Cancer”

Dr. Richard Peek is a Professor of Medicine at Vanderbilt University. “The overarching theme for our research has been delineation of the signaling events initiated by bacterial:epithelial cell contact that regulate carcinogenic phenotypes using complementary model systems. We utilize ex vivo gastric organoid systems that closely recapitulate cellular organization in the stomach to examine aberrant responses to oncogenic H. pylori strains. We also developed robust and reproducible rodent models of H. pylori-induced gastric cancer. We have continually extended our observations into human populations, and have recently examined interactions between host and pathogen genetic ancestry that influence gastric cancer development in persons at high or low risk for disease. Collectively, our group has made fundamental discoveries regarding gastric cancer pathogenesis that have significantly influenced understanding of the disease and management of patients, and which have provided a foundation for other investigations focused on inflammation-mediated carcinogenesis.”

Charles Rabkin, MD
National Institutes of Health
National Cancer Institute
“EBV Associated Gastric Cancers ”

Dr. Charles Rabkin earned an Sc.B. and M.D. from Brown University and an M.Sc. in epidemiology from the London School of Hygiene and Tropical Medicine. He received postgraduate training at the University of Colorado and is board certified in internal medicine and preventive medicine. Before coming to the NCI, he was an Epidemic Intelligence Service Officer and a medical epidemiologist at the Centers for Disease Control and Prevention.
KEITH WILSON, MD
Vanderbilt University
“Helicobacter pylori, Polyamines, and Gastric Cancer”

Dr. Keith Wilson is a physician-scientist gastroenterologist, who has a longstanding interest in gastrointestinal mucosal immunology, inflammation, and carcinogenesis. This includes a focus on Helicobacter pylori and the host response to the infection, and numerous studies investigating the molecular pathogenesis of the progression to gastric cancer. In his laboratory and research center, the overarching goal is to understand the links between chronic GI inflammation and cancer, with the goal of developing novel interventions to prevent cancer.

MANUEL AMIEVA, MD, PHD
Stanford University
“Gastric Cancer from H. pylori’s perspective”

Dr. Manuel Amieva’s research focus is on understanding how bacterial pathogens colonize epithelial surfaces and how epithelial colonization leads to infection and disease. He grew up in Mexico City and fell in love with the wonders of biology as an undergraduate at Dartmouth College, where he was taught multiple skills in microscopy and studied the development of marine invertebrates. Afterwards, Dr. Amieva returned to Mexico and wrote children’s books that were recorded as radioplays and retold his countless adventures in science and biology. He then moved to California to pursue an M.D./Ph.D. at Stanford University. During his Ph.D., Dr. Amieva studied how cytoskeletal proteins aid in cell movement in the laboratory of Heinz Furthmayr. Following completion of a residency in Pediatrics at Lucille Packard Children’s Hospital, Dr. Amieva became a Pediatric Infectious Diseases Fellow at Stanford and further trained as a postdoctoral scholar in the laboratory of Stanley Falkow. An avid microscopist, Dr. Amieva loves to hide in the microscope room where he can spend countless hours on the confocal looking through the porthole at microbes interacting with cells and tissues.

Lunch Break
Gastric Cancer 2050, Shifting Burdens and Demographics

Fernando Alarid-Escudero, PhD
Center for Research and Teaching in Economics
“Modeling Gastric Cancer into the 21st century”

Dr. Fernando Alarid-Escudero, is an assistant professor in the Drug Policy Program at the Center for Research and Teaching in Economics (CIDE) in Mexico. He is also a member of the Cancer Intervention Surveillance Modeling Network (CISNET) consortium and a technical advisor to the Canadian Institute for Health Information (CIHI). He focuses on developing and applying new methods in medical decision making, simulation modeling and cost-effectiveness analysis. His applied work focuses on the use of simulation models to evaluate and identify optimal clinical and public health strategies, such as treatment and screening for cancer, including gastric, colorectal and cervical cancer. He developed a simulation model of H. pylori infection and gastric cancer, used to estimate the cost-effectiveness of different screen-and-treat strategies of H. pylori accounting for antibiotic resistance.

Christian C Abnet, PhD, MPH
National Institutes of Health
National Cancer Institute
“Gastric Cardia Cancer in Eastern and Western Populations”

Dr. Christian Abnet earned a PhD in Environmental Toxicology and an MPH in Epidemiology and joined the National Cancer Institute in 1998. Dr. Abnet’s work focuses on the etiology of esophageal and gastric cancer. His research interests are driven by a desire to meet the needs of populations in limited-resource settings who are at highest risk for these diseases.
Constanza Camargo, PhD
National Institutes of Health
National Cancer Institute
“The Changing Face of Non-Cardia Gastric Adenocarcinoma”

Dr. Constanza Camargo is a cancer epidemiologist originally from Colombia. She is an Earl Stadtman Investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute. Dr. Camargo’s research program focuses on Helicobacter pylori infection, premalignant gastric lesions and gastric cancer. As a smaller research effort, she conducts studies of esophageal squamous cell carcinoma with an emphasis on the potential etiologic role of infections. In both lines of research, her program combines studies on cancer causation with projects that may have translational application for cancer screening, prevention and treatment.

Michael Bruce, MD
Center for Disease Control
“Gastric Cancer among Alaskan Natives”

Dr. Michael Bruce is a public health physician and medical epidemiologist trained in Internal and Preventive Medicine. He is the Director of the Centers for Disease Control and Prevention’s Arctic Investigations Program (AIP) in Anchorage, Alaska, USA.

He joined CDC as an EIS officer in 1997, serving with the Meningitis & Special Pathogens Branch, then completed a preventive medicine residency at the Washington State Health Department before joining AIP as a medical epidemiologist in 2000. He became the Epidemiology Team Lead in 2006 and has led the team to conduct research on a range of infectious diseases that disproportionally affect Alaskan, Alaska Native, and Arctic peoples. Michael is an internationally recognized expert on Haemophilus influenzae serotype a, and H. pylori and helped establish an ongoing H. pylori sentinel surveillance system in Alaska. He is the US representative to the Arctic Council’s Arctic Human Health Expert Group (AHHEG). He earned an MD and MPH from Tufts University School of Medicine and School of Public Health, respectively. He earned an undergraduate degree (cum laude) in Anthropology from UCLA. For the past 20 years, his work has focused on improving the health of Alaskans and peoples of the Arctic. He has received numerous awards and has published over 130 scientific articles and book chapters.
March 6th - Session Four Speakers

Moderator: Robert Huang, MD, MS

Advancing Early Detection

Blanca Piazuelo, MD
Vanderbilt University
“Understanding the spectrum of gastric atrophy: OLGA and OLGIM staging systems”

Dr. Maria Blanca Piazuelo earned a degree in Medicine at Universidad del Valle in Colombia and completed a residence in Pathology at the same institution. She was then recruited by Dr. Pelayo Correa, with whom she trained and worked in gastric pathology for more than a decade. Dr. Piazuelo is currently a Research Associate Professor in the Division of Gastroenterology at Vanderbilt University Medical Center. Her research work is focused on the pathology of precancerous lesions of the stomach associated with Helicobacter pylori infection.

Hanlee Ji, MD
Stanford University
“Molecular pathways of gastric cancer and intestinal metaplasia, insights from single cell transcriptomics.”

Dr. Hanlee Ji’s research interest is cancer genetics with an emphasis on clinically relevant questions that will improve our understanding of the cancer genetics of clinical phenotype and simultaneously improve patient care in oncology. He has performed and directed extensive bench research experience in the fields of genome sequencing technology development, human genetic analysis through human genome sequencing and molecular assay development. His research benefits from the various innovations in genomic and genetic technologies that his group has developed. One of the major topics of his research program involves elucidating the genetic mechanisms and biology underlying the metastatic spread of cancers with a specific focus on gastrointestinal malignancies. His group has also developed multiple bioinformatic methods and resources for application in cancer genome and genetic analysis. These tools and databases have served as the basis for several discoveries by his group and others.
Dr. Jeremy Davis is a surgical oncologist and clinical investigator in the Center for Cancer Research, National Cancer Institute (NCI), at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Davis completed his surgery training at Indiana University and an additional three years of cancer research at the NCI. He received advanced training in surgical oncology at Memorial Sloan Kettering Cancer Center and is board certified in both Complex General Surgical Oncology and General Surgery. He currently serves as Surgeon-in-Chief of the NIH Clinical Center, “America’s Research Hospital” and Program Director for the NCI Surgical Oncology Research Fellowship. Dr. Davis’ research focus is hereditary stomach cancers, specifically those caused by germline mutations in the CDH1 gene, and the molecular underpinnings of gastric cancer development and metastasis. He is the principal investigator of four active stomach cancer studies being conducted at NIH Clinical Center.

Dr. Elena Stoffel is Director of the Cancer Genetics Clinic at the University of Michigan in Ann Arbor, MI. She trained in Internal Medicine and Gastroenterology at Brigham and Women’s Hospital and earned her MPH in Clinical Effectiveness from the Harvard School of Public Health. Dr. Stoffel’s clinical and research interests focus on diagnosis and management of individuals with genetic predisposition to cancer, specifically developing strategies to improve early detection and cancer prevention. Dr. Stoffel serves on the American Society of Clinical Oncology Cancer Genetics Subcommittee and is a past President of the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC).
Thank you for attending the

**Stanford Gastric Cancer Summit**

All presentations are available to view live online!

*link provided below

**HTTPS://LIVESTREAM.COM/ACCOUNTS/1973198/GASTRIC**